Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by William Blair Investment Management LLC

William Blair Investment Management LLC increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,597,698 shares of the biopharmaceutical company’s stock after acquiring an additional 14,736 shares during the period. William Blair Investment Management LLC owned about 5.22% of Amicus Therapeutics worth $146,930,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of FOLD. KBC Group NV grew its holdings in Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,120 shares during the period. Swiss National Bank grew its holdings in Amicus Therapeutics by 0.7% in the fourth quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company’s stock valued at $4,121,000 after purchasing an additional 3,200 shares during the period. Legacy Capital Group California Inc. grew its holdings in Amicus Therapeutics by 20.2% in the fourth quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 3,900 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Amicus Therapeutics in the third quarter valued at approximately $55,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Amicus Therapeutics by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company’s stock valued at $597,000 after purchasing an additional 6,314 shares during the period.

Analysts Set New Price Targets

Several analysts have commented on FOLD shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Wells Fargo & Company dropped their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $8.90 on Monday. Amicus Therapeutics, Inc. has a one year low of $8.55 and a one year high of $12.65. The company has a market cap of $2.73 billion, a price-to-earnings ratio of -49.44, a PEG ratio of 1.51 and a beta of 0.69. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The business’s 50 day moving average price is $9.38 and its 200 day moving average price is $10.14.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.